Criteria |
1 | Onset of pain after exposure to chemotherapeutic agent known to be neurotoxic |
2 | Presence of painful symptoms in a symmetrical stocking and glove distribution beginning in lower extremities, which may progress to the upper extremities, although finding in the feet and not in the hands is common |
3 | Painful symptoms are accompanied by nonpainful symptoms (eg, "pins and needles" or numbness) in a similar distribution |
4 | Clinical examination reveals sensory loss to 1 or more sensory modalities and/or evoked pain in a stocking and glove distribution, as reflected in at least 1 of the following: - Bilateral increase in detection thresholds to tactile, vibration, or non-noxious warm or cool stimuli
- Bilateral increase in pain detection thresholds to blunt pressure or pinprick stimuli
- Bilateral decrease in pain detection threshold to noxious heat or cold stimuli
|
5 | Magnitude of the sensory abnormalities is disproportionately greater than the magnitude of any motor abnormalities in the affected region (except in the case of neuropathy after vinca alkaloids) |
6 | No other condition (eg, polyneuropathy of other origin) could plausibly account for painful symptoms |